WST · 10-Q · 2026Q3 · Full report
Gross Margin Drivers
WEST PHARMACEUTICAL SERVICES INC · 2026-10-29 · Importance 48 · Surprise 40 · In source text
Consolidated gross profit for the third quarter of 2026 increased $53.1 million, or 18.0%, to $347.4 million, and gross margin expanded 3.1 percentage points to 39.7%; nine-month gross profit rose $172.9 million, or 21.6%, to $973.0 million, and margin expanded 2.2 points to 37.5%. Proprietary Products’ third-quarter margin improved 3.6 points to 44.4%, primarily from favorable HVP components mix, including GLP-1 products, and price increases, partly offset by inflation and plant costs. West Vantage’s third-quarter margin declined 2.8 points to 16.5%, reflecting product mix, inflationary plant spending, and drug-handling program ramp-up costs, partly offset by price increases. For the first nine months, West Vantage margin fell 2.3 points to 15.4%, partly because of production downtime associated with the May 2026 cyber incident and inflationary plant spending.
Key facts
- WEST PHARMACEUTICAL SERVICES INC’s consolidated gross profit increased $172.9 million, or 21.6%, in the nine months ended September 30, 2026, while gross profit margin increased 2.2 percentage points. source
- WEST PHARMACEUTICAL SERVICES INC’s consolidated gross profit increased $53.1 million, or 18.0%, in the three months ended September 30, 2026, while gross profit margin increased 3.1 percentage points. source
- In February 2026, the U.S. Supreme Court ruled that certain tariffs imposed under IEEPA were unauthorized; during the second quarter of 2026, WEST PHARMACEUTICAL SERVICES INC began applying for and receiving certain refunds for tariffs previously collected under IEEPA. source
- WEST PHARMACEUTICAL SERVICES INC does not expect tariff and trade-restriction matters to have a material impact on its 2026 results, based on information currently available. source
- WEST PHARMACEUTICAL SERVICES INC does not expect Middle East conflict-related matters to materially affect its results of operations, financial condition, or liquidity, based on available information and mitigation efforts. source
- WEST PHARMACEUTICAL SERVICES INC’s West Vantage gross profit margin decreased 2.3 percentage points in the nine months ended September 30, 2026, due to production downtime related to the May 2026 cyber incident and inflationary plant spend, partially offset by price increases. source
- WEST PHARMACEUTICAL SERVICES INC’s Proprietary Products gross profit margin increased 3.6 percentage points in the three months ended September 30, 2026, primarily due to favorable HVP components mix, including GLP-1 products, and price increases, partially offset by inflation and plant costs. source
- WEST PHARMACEUTICAL SERVICES INC’s Proprietary Products gross profit margin increased 2.7 percentage points in the nine months ended September 30, 2026, primarily due to favorable HVP components mix and price increases, offset by inflationary pressures and plant performance. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | positive | realized | +19.8% | WEST PHARMACEUTICAL SERVICES INC’s consolidated gross profit increased $172.9 million, or 21.6%, in the nine months ended September 30,… |
| margin | positive | realized | +2.2% | WEST PHARMACEUTICAL SERVICES INC’s consolidated gross profit increased $172.9 million, or 21.6%, in the nine months ended September 30,… |